Asunaprevir/daclatasvir Reactions 1680, p60 - 2 Dec 2017 Various toxicities: 4 case reports In a single centre retrospective longitudinal observational study, four elderly patients [sexes and specific ages not stated] were described, who developed elevated serum AST and ALT levels (1 patient), fever and fatigue (1 patient), appetite loss and nausea (1 patient) and fatigue and dysphasia (1 patient) during treatment with daclatasvir and asunaprevir [times to reactions onsets and outcomes not stated]. All the patients had a history of chronic hepatitis C virus genotype 1b infection and liver dysfunction. Out of these four patients, three patients were included in chronic kidney disease (CKD) group, and the remaining patient was included in non-CKD group of the retrospective study. All the patients received antiviral therapy, which consisted of oral daclatasvir 60mg once daily after breakfast, and oral asunaprevir 100mg twice daily after breakfast and after supper. Various parameters including serum AST and ALT levels were routinely monitored. Subsequently, the patients developed elevated serum AST and ALT levels (n=1), fever and fatigue (n=1), appetite loss and nausea (n=1) and fatigue and dysphasia (n=1). The antiviral therapy was discontinued in all four patients. Author comment: "Adverse effects were comparable between the two groups." "The patients received oral administration of 60mg [daclatasvir] once a day after breakfast and 100mg [asunaprevir] twice a day". "Three patients in the CKD group withdrew the treatment due to the elevation in serum AST and ALT levels in 1 patient, fever and fatigue in 1, and appetite loss and nausea in 1". "[I]n the non-CKD group. . .fatigue and dysphasia in 1". Morisawa N, et al. Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease. Clinical and Experimental Nephrology 21: 818-824, No. 5, Oct 2017. Available from: URL: - Japan 803283897 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial